GENMAB'S R&D TO COMMERCIALISATION JOURNEY (REDUCE; -10% DOWNSIDE)
03/09/21 -" Soon after our last teaser (GENMAB’S LIFE BEYOND DARZALEX) in May 2020, Genmab (Reduce, Denmark) announced a big oncology pact with AbbVie (US pharma heavyweight). Importantly, the Danish biotech – ..."
Pages
50
Language
English
Published on
03/09/21
You may also be interested by these reports :
13/08/26
PolyPeptide released its already-known results, with no surprises. There was strong operational performance, with guidance raised for FY26. The focus ...
13/08/26
The Q2 results surpassed expectations, backed by the unrelenting growth of Dupixent and the impressive uptake of some newly launched medicines. ...
12/08/26
With the Astra-BMS merger idea likely being shelved after apprehensions raised by various analysts/investors, we re-float the idea of an Astra-GSK ...
04/08/26
Imagine a restaurant having to serve its customers by ordering outside food. We cannot resist drawing parallels between this hypothetical scenario ...